SCLX Scilex Holding Co
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1820190 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-28.5%
TTM net income YoY-473.7%
TTM EPS YoY-2,120.1%
Revenue 3-yr CAGR-12.0%
Net income 3-yr CAGR—
Margins
Gross margin161.1%
Operating margin-1,136.4%
Net margin-1,469.8%
FCF margin—
EBITDA margin-1,119.8%
Returns
ROE—
ROA-275.4%
ROIC (approx.)—
Asset turnover0.19x
Leverage & solvency
Liabilities / assets222.5%
Debt / equity—
Current ratio0.07x
Interest coverage-22.20x
Cash quality & payout
Operating cash flow / net income0.04x
Accruals ratio-265.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $30.25M | $56.59M | $46.74M | $38.03M | $31.32M |
| Cost of revenue | $10.60M | $16.69M | $15.68M | $10.80M | $3.63M |
| Gross profit | $125.80M | $167.40M | $31.06M | $27.24M | $27.68M |
| R&D expense | $20.71M | $9.64M | $12.75M | $9.05M | $9.20M |
| SG&A expense | $266.88M | $119.02M | $119.64M | $64.89M | $50.58M |
| Operating income | -$346.01M | -$83.40M | -$105.43M | -$50.63M | -$35.84M |
| Interest expense | $11.46M | $1.96M | $1.07M | $9.60M | $11.76M |
| Pretax income | -$374.03M | -$72.81M | -$114.32M | -$23.36M | -$88.42M |
| Income tax | $26,000 | -$1,000 | $13,000 | $4,000 | $5,000 |
| Net income | -$374.05M | -$72.81M | -$114.33M | -$23.36M | -$88.42M |
| EBITDA | -$341.38M | -$79.35M | -$101.28M | -$46.67M | -$32.06M |
| EPS (basic) | -36.48 | -7.24 | -1.28 | -0.17 | -0.67 |
| EPS (diluted) | -36.48 | -8.05 | -1.28 | -0.17 | -0.67 |
| Weighted avg. shares (diluted) | 11,034 | 10,145 | 130.30M | 134.23M | 132.86M |
| Balance sheet | |||||
| Cash & equivalents | $4.96M | $3.27M | $4.73M | $2.18M | $4.34M |
| Short-term investments | — | — | — | — | $303,753 |
| Receivables | $15.24M | $26.44M | $34.60M | $21.24M | $14.27M |
| Inventory | $4.79M | $2.44M | $4.21M | $1.38M | $2.56M |
| Current assets | $38.36M | $41.55M | $46.78M | $29.61M | $23.00M |
| PP&E, net | $13.60M | $708,000 | $722,000 | $772,000 | $805,000 |
| Goodwill | $13.48M | $13.48M | $13.48M | $13.48M | $13.48M |
| Intangibles | $59.09M | $32.45M | $36.48M | $40.59M | $38.80M |
| Total assets | $364.98M | $92.95M | $101.31M | $86.53M | $77.93M |
| Current liabilities | $483.65M | $259.63M | $250.38M | $44.84M | $169.42M |
| Short-term debt | $83.26M | $34.88M | $108.43M | $0 | $29.14M |
| Long-term debt | — | — | — | $0 | $72.04M |
| Total debt | — | — | — | $0 | $101.17M |
| Total liabilities | $576.73M | $285.59M | $274.25M | $50.29M | $301.81M |
| Shareholders' equity | -$207.78M | -$192.64M | -$172.94M | $36.24M | -$223.88M |
| Net debt | — | — | — | -$2.18M | $96.83M |
| Shares outstanding | 7.03M | 5.24M | 100.02M | 141.35M | 132.86M |
| Cash flow statement | |||||
| Operating cash flow | $3.82M | $19.35M | -$20.71M | -$21.26M | -$28.66M |
| Capital expenditure | $133,000 | $0 | $30,000 | $7,000 | $0 |
| Free cash flow | $3.68M | $19.35M | -$20.74M | -$21.27M | -$28.66M |
| Investing cash flow | $4.08M | -$2.67M | -$330,000 | -$2.07M | $0 |
| Financing cash flow | -$5.46M | -$18.13M | $23.58M | $21.17M | $28.16M |
| Depreciation & amortization | $4.62M | $4.05M | $4.15M | $3.96M | $3.78M |
| Stock-based compensation | $15.49M | $15.69M | $14.60M | $5.28M | $5.82M |
| Dividends paid | — | $8.65M | $8.65M | — | — |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.